Metraipolis › archive › dc_d97f62665880

Aroxybutynin and atomoxetine (AD109) for the treatment of obstructive sleep apnea: Rationale, design and baseline characteristics of the phase 3 clinical trials — Europe PMC PMID:41050845

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41050845
DOI
10.1016/j.conctc.2025.101538
License (as archived)
solo-consultazione
Archived
2026-11-10T13:51:06.063Z
SHA-256 of the archived text
c1ad4acb8fd5d3ddcdc63d6596556e9f21dd8e3bfc19711349ffeaa379415360
Stable URL of this page
https://metraipolis.com/documento/dc_d97f62665880

How to cite

Aroxybutynin and atomoxetine (AD109) for the treatment of obstructive sleep apnea: Rationale, design and baseline characteristics of the phase 3 clinical trials — Europe PMC PMID:41050845 — Europe PMC (en), https://europepmc.org/article/MED/41050845 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_d97f62665880 (Metraipolis archive dc_d97f62665880, sha256 c1ad4acb8fd5d3ddcdc63d6596556e9f21dd8e3bfc19711349ffeaa379415360)
BibTeX
@misc{dcd97f62665880,
  title = {Aroxybutynin and atomoxetine (AD109) for the treatment of obstructive sleep apnea: Rationale, design and baseline characteristics of the phase 3 clinical trials — Europe PMC PMID:41050845},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41050845},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_d97f62665880; sha256 c1ad4acb8fd5d3ddcdc63d6596556e9f21dd8e3bfc19711349ffeaa379415360},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41050845. Agents can read the archived copy with the MCP tool read_document.